During the partnering conference Bio-Europe Spring in Lisbon, we reached Pila Pharma's ceo Gustav H. Gram via link for an update. With funding secured into 2027, the company is now experiencing growing interest in its oral TRPV1 antagonist as a challenger in the obesity market. In the interview, Gustav H. Gram shares his impressions from the conference and the market's appetite for new mechanisms of action outside the GLP-1 sphere. Furthermore, he discusses the upcoming CTA application for a rare pain disorder and which milestone he is most looking forward to delivering on this spring.